Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Importance Colorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52 980 persons in the US projected to die of colorectal cancer in 2021. Colorectal cancer is most frequently diagnosed among persons aged 65 to 74 years. It is estimated that 10.5% of new colorectal cancer cases occur in persons younger than 50 years. Incidence of colorectal cancer (specifically adenocarcinoma) in adults aged 40 to 49 years has increased by almost 15% from 2000-2002 to 2014-2016. In 2016, 26% of eligible adults in the US had never been screened for colorectal cancer and in 2018, 31% were not up to date with screening. Objective To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for colorectal cancer in adults 40 years or older. The review also examined whether these findings varied by age, sex, or race/ethnicity. In addition, as in 2016, the USPSTF commissioned a report from the Cancer Intervention and Surveillance Modeling Network Colorectal Cancer Working Group to provide information from comparative modeling on how estimated life-years gained, colorectal cancer cases averted, and colorectal cancer deaths averted vary by different starting and stopping ages for various screening strategies. Population Asymptomatic adults 45 years or older at average risk of colorectal cancer (ie, no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]). Evidence Assessment The USPSTF concludes with high certainty that screening for colorectal cancer in adults aged 50 to 75 years has substantial net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has moderate net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 76 to 85 years who have been previously screened has small net benefit. Adults who have never been screened for colorectal cancer are more likely to benefit. Recommendation The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation) The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. (B recommendation) The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient’s overall health, prior screening history, and preferences. (C recommendation)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Centers for Disease Control and Prevention
(2007) · Encyclopedia of Measurement and Statistics · doi:10.4135/9781412952644.n74 · Cited by 6,444
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,806
American Academy of Family Physicians
(1966) · New England Journal of Medicine · doi:10.1056/nejm196611172752014 · Cited by 1,948
Wolf, A. M. D., Fontham, E. T. H., Church, T. R., Flowers, C. R., Guerra, C. E., LaMonte, S. J., Etzioni, R., McKenna, M. T., Oeffinger, K. C., Shih, Y. T., et al. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21457 · Cited by 1,944
Multitarget Stool DNA Testing for Colorectal-Cancer Screening
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311194 · Cited by 1,900
Long-term colorectal-cancer incidence and mortality after lower endoscopy
Nishihara, R., Wu, K., Lochhead, P., Morikawa, T., Liao, X., Qian, Z. R., Inamura, K., Kim, S. A., Kuchiba, A., Yamauchi, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301969 · Cited by 1,483
Colorectal Cancer Incidence Patterns in the United States, 1974–2013
Siegel, R. L., Fedewa, S. A., Anderson, W. F., Miller, K. D., Ma, J., Rosenberg, P. S., & Jemal, A. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw322 · Cited by 1,002
Bibbins-Domingo, K., & on behalf of the U.S. Preventive Services Task Force* (2016) · Annals of Internal Medicine · doi:10.7326/m16-0577 · Cited by 854
ACG Clinical Guidelines: Colorectal Cancer Screening 2021
Shaukat, A., Kahi, C. J., Burke, C. A., Rabeneck, L., Sauer, B. G., & Rex, D. K. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001122 · Cited by 853
Lin, J. S., Perdue, L. A., Henrikson, N. B., Bean, S. I., & Blasi, P. R. (2021) · JAMA · doi:10.1001/jama.2021.4417 · Cited by 650
Faivre, J., Dancourt, V., Lejeune, C., Tazi, M. A., Lamour, J., Gerard, D., Dassonville, F., & Bonithon-Kopp, C. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.018 · Cited by 460
Rex, D. K., Boland, C. R., Dominitz, J. A., Giardiello, F. M., Johnson, D. A., Kaltenbach, T., Levin, T. R., Lieberman, D., & Robertson, D. J. (2017) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.04.003 · Cited by 460
United States Life Tables, 2018.
Arias, E., & Xu, J. (2020) · PubMed · Cited by 373
Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force
Knudsen, A. B., Rutter, C. M., Peterse, E. F. P., Lietz, A. P., Seguin, C. L., Meester, R. G. S., Perdue, L. A., Lin, J. S., Siegel, R. L., Doria-Rose, V. P., et al. (2021) · JAMA · doi:10.1001/jama.2021.5746 · Cited by 327
Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up
Scholefield, J. H., Moss, S. M., Mangham, C. M., Whynes, D. K., & Hardcastle, J. D. (2012) · Gut · doi:10.1136/gutjnl-2011-300774 · Cited by 297
Kronborg, O., Jørgensen, O. D., Fenger, C., & Rasmussen, M. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410003182 · Cited by 262
Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018
Joseph, D. A., King, J. B., Dowling, N. F., Thomas, C. C., & Richardson, L. C. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6910a1 · Cited by 207
Qaseem, A., Crandall, C. J., Mustafa, R. A., Hicks, L. A., Wilt, T. J., Forciea, M. A., Fitterman, N., Horwitch, C. A., Kansagara, D., Maroto, M., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0642 · Cited by 186
Lansdorp-Vogelaar, I., Gulati, R., Mariotto, A. B., Schechter, C. B., de Carvalho, T. M., Knudsen, A. B., van Ravesteyn, N. T., Heijnsdijk, E. A. M., Pabiniak, C., van Ballegooijen, M., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2867 · Cited by 148
García-Albéniz, X., Hsu, J., Bretthauer, M., & Hernán, M. A. (2017) · Annals of Internal Medicine · doi:10.7326/m16-0758 · Cited by 142
Miller, E. A., Pinsky, P. F., Schoen, R. E., Prorok, P. C., & Church, T. R. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30358-3 · Cited by 112
Montminy, E. M., Zhou, M., Maniscalco, L., Abualkhair, W., Kim, M. K., Siegel, R. L., Wu, X.-C., Itzkowitz, S. H., & Karlitz, J. J. (2021) · Annals of Internal Medicine · doi:10.7326/m20-0068 · Cited by 103
Secular Trends in Colon and Rectal Cancer Relative Survival
Rutter, C. M., Johnson, E. A., Feuer, E. J., Knudsen, A. B., Kuntz, K. M., & Schrag, D. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt299 · Cited by 87
Rutter, C. M., Knudsen, A. B., Lin, J. S., & Bouskill, K. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-1537 · Cited by 83
Performance of multitarget stool DNA testing in African American patients
Cooper, G. S., Markowitz, S. D., Chen, Z., Tuck, M. K., Willis, J. E., Berger, B. M., Brenner, D. E., & Li, L. (2018) · Cancer · doi:10.1002/cncr.31660 · Cited by 33
Self-citationRacial Disparities in Colorectal Cancer Survival: Is Elimination of Variation in Care the Cure?
Doubeni, C. A., & Rustgi, A. K. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv229 · Cited by 16
Self-citation
Cited by
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21871 · Cited by 3,060
Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death
Bretthauer, M., Løberg, M., Wieszczy, P., Kalager, M., Emilsson, L., Garborg, K., Rupinski, M., Dekker, E., Spaander, M., Bugajski, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208375 · Cited by 817
Patel, S. G., Karlitz, J. J., Yen, T., Lieu, C. H., & Boland, C. R. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00426-x · Cited by 812
Current and future colorectal cancer screening strategies
Shaukat, A., & Levin, T. R. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00612-y · Cited by 516
Metadata
- Authors
- US Preventive Services Task Force, Davidson, K. W., Barry, M. J., Mangione, C. M., Cabana, M., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Krist, A. H., Kubik, M., Li, L., Ogedegbe, G., Owens, D. K., Pbert, L., Silverstein, M., Stevermer, J., Tseng, C.-W., & Wong, J. B.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-05-18
- Volume
- 325
- Issue
- 19
- Pages
- 1965
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4231576061
- Cited by
- 2,034
- References
- 26
- FWCI
- 96.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.